Program

The meeting room is located on Level +4, Hall 400
(Coffee & Lunch breaks take place on Level +1, Hall 100)

THURSDAY 8 SEPTEMBER 2016

- 9.00 – 9.15: Welcome from key members of the four organizing bodies
- 9.15 – 9.30: EU efforts for cancer personalized medicine (Irene Norstedt)

SESSION 1: Chairs | Roberto Salgado & Helen Moore
QA & QC from pre analytical steps to clinical utility
- 9.30 – 9.50: Quality management in the collection and management of biospecimens for clinical trials biobanking and why this impact health care (Hartmut Juhl)
- 9.50 – 10.10: When is an assay “ready” for the clinic with regard to quality management from the health care perspective? Who decides this, and what information do they use to decide? (Erasmus Schneider)
- 10.10 – 10.30: Quality standards for clinical genomic tests and why this is important for health care (Christine Vietz)
- 10.30 – 11.00: PANEL DISCUSSION: Out of the box approaches on use of new emerging technologies (e.g. next generation sequencing) in health care and why a QA assessment by health care systems responsible for payment is imperative (Chairs & Speakers of the Session)

11.00 – 11.30: Coffee Break

SESSION 2: Chairs | John Martens & Tracy Lively
Considerations in assay development and its integration into drug development: Clinical trials and beyond into clinical practice
- 11.30 – 12.00: Overview of assay development for early stage clinical trials, and importance of the dialog between trialists and laboratorians (Robert Kinders)
- 12.00 – 12.20: Development and application of validated immunohistochemical assays for patient selection, pharmacodynamic endpoints in clinical trials (Stephen Hewitt)
- 12.20 – 12.40: Innovative imaging techniques to visualize drug targets (Guus van Dongen)
- 12.40 – 13.00: Preclinical and translational challenges in cancer immunotherapy development (Simon Dovedi)

13.00 – 14.00: Lunch Break

SESSION 3: Chairs | Denis Lacombe & Shakun Malik
Patient access and regulatory challenges for clinical trials in the era of molecularly defined “Personalized therapies”
- 14.00 – 14.10: Screening Patients for Efficient Clinical Trial Access (Vassilis Golfinopoulos)
- 14.10 – 14.20: NCI’s precision medicine initiatives (Shakun Malik)
- 14.20 – 14.30: Evolving regulatory science: can we keep pace (Daniel O’Connor)
- 14.40 – 14.50: Japanese point of view (Sumimasa Nagai)
- 14.50 – 15.40: PANEL DISCUSSION (Jan Bogaerts, Herbert Kim Lyerly, Thomas Lillie, Stefan Michiels, Kathy Oliver, Adrian Senderowicz, Chairs & Speakers of the Session)

15.40 – 16.10: Coffee Break
SESSION 4: Chairs | Elaine Mardis & Ultan McDermott
Bioinformatic approaches to big data analysis and the clinical decision process

- 16.10 – 16.30: Genomic characterisation and risk stratification of acute myeloid leukemia (Moritz Gerstung)
- 16.30 – 16.50: Decision support pipelines and tools for translational cancer genomics (Elaine Mardis)
- 16.50 – 17.10: Next steps- taking complex genomic analysis in routine clinical practice (Philip Beer)
- 17.10 – 17.40: PANEL DISCUSSION (Stefan Michiels, Erasmus Schneider, Chairs & Speakers of the Session)

FRIDAY 9 SEPTEMBER 2016 (morning)

SESSION 5: Chairs | Jeffrey Moscow & Richard Sullivan
DEBATE Impact on health care systems, a multi stakeholder societal challenge for research, pharma and patients

- 9.00 – 9.45: AGAINST the notion that precision cancer medicine can be delivered in a sustainable and affordable manner (Tito Fojo & Daniel Hochhauser)
- 9.45 – 10.30: FOR the notion that precision cancer medicine can be delivered in a sustainable and affordable manner (Richard Schilsky & Nils Wilking)

10.30 – 11.00: Coffee Break

SESSION 6: Chairs | Sabine Tejpar & Tawnya McKee
Horizons: Biomarker Signatures Beyond NGS. A bird’s-eye-view of the future of biomarkers on guiding drug development

- 11.00 – 11.30: TCGA or ICGC omics data as a static snapshot of tumors combining omics data (CPTAC with TCGA/ICGC) produces a unified snapshot of tumors (Mehdi Mesri)
- 11.30 – 12.00: Monitoring the cancer genome in plasma using circulating tumour DNA (Nitzan Rosenfeld)
- 12.00 – 12.30: Targeting cancer metastasis through circulating tumor cells (Shyamala Maheswaran)

Rapporteur of the event: Peter O’Donnell